DNA Vaccines for the Induction of Immune Responses in Mucosal Tissues

Raška, Milan; Tuřánek, Jaroslav

doi:10.1016/b978-0-12-415847-4.00067-7

Cited by 11 publications

(13 citation statements)

References 271 publications

(226 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 0.05-mg hgalactosidase (LacZ)-expressing plasmid DNA (pCMVh) was injected five times into a single cutaneous lesion; no serious side effects were observed. In several clinical trials on the needle-free administration of HIV-1 antigens EnvA-, EnvB-, EnvC-, gagB-, polB-and nefB-encoding DNA vaccines (including HVTN204), followed by boosting with rAd5containing matching inserts, cellular and humoral immune responses were elicited [78,79].…”

Section: Gene Therapymentioning

confidence: 99%

Current engineering and clinical aspects of needle-free injectors: A review

Mohizin

Kim

2018

J Mech Sci Technol

View full text Add to dashboard Cite

Needle-free injectors can be used to achieve non-invasive drug delivery by impregnating biological barriers. They are considered as the future of drug delivery and therapeutic applications. The history of needle-free injectors dates back to the 1940s and these devices have been constantly evolving since then. Their operating principles and applications have been improved over the years. Herein, we review the current engineering mechanisms and clinical aspects of needle-free microjet injectors. The present study focuses on using engineering approaches to deal with various factors that affect the penetration and dispersion characteristics of the microjet.

show abstract

Section: Gene Therapymentioning

confidence: 99%

Current engineering and clinical aspects of needle-free injectors: A review

Mohizin

Kim

2018

J Mech Sci Technol

View full text Add to dashboard Cite

show abstract

“…[94] Epidermal DNA vaccines delivered via a gene gun have been shown to elicit both humoral and cell-mediated mucosal immune responses in experimental animals and cattle [63,95,96]. This needle-free technology is based on propelling DNA-coated colloidal gold microprojectiles at exposed tissue surfaces (e.g.…”

Section: Improving Mucosal Vaccinesmentioning

confidence: 99%

“…skin, vulva and mouth) and penetrating the cytosol and cell nucleus of cells within deeper layers of the tissue. [94] Epidermal DNA vaccines delivered via a gene gun have been shown to elicit both humoral and cell-mediated mucosal immune responses in experimental animals and cattle [63,95,96]. To improve the potency of immune responses gene to gun gene immunizations, DNA can be combined with adjuvants such as recombinant protein antigens and plasmids encoding cytokines [94,97].…”

Section: Improving Mucosal Vaccinesmentioning

confidence: 99%

Mucosal vaccines and technology

Miquel-Clopés

Bentley

Stewart

et al. 2019

Clinical and Experimental Immunology

116

124

View full text Add to dashboard Cite

Summary There is an urgent and unmet need to develop effective vaccines to reduce the global burden of infectious disease in both animals and humans, and in particular for the majority of pathogens that infect via mucosal sites. Here we summarise the impediments to developing mucosal vaccines and review the new and emerging technologies aimed at overcoming the lack of effective vaccine delivery systems that is the major obstacle to developing new mucosal vaccines.

show abstract

“…Another promising DNA delivery strategy is gene gunning where plasmid DNA is coated with heavy metals ( e.g. gold particles) and bombarded into APCs at the injection site, which decreased the required plasmid DNA dose by 100–1,000 fold[65, 66]. Although a variety of strategies have been developed to improve DNA vaccine delivery, these vaccines still possess low immunogenicity profiles in human trials for reasons not yet fully understood[58, 67].…”

Section: Different Types Of Vaccines and Their Clinical Statusmentioning

confidence: 99%

Biomaterials for vaccine-based cancer immunotherapy

Zhang

Billingsley

Mitchell

2018

Journal of Controlled Release

155

120

View full text Add to dashboard Cite

The idea of developing therapeutic vaccines against cancer has been explored since the early discovery of tumor-specific antigens by Georg Klein in 1967. However, challenges including weak immunogenicity, systematic toxicity, and off-target effects of cancer vaccines remain as barriers to their broad clinical translation. The emerging field of biomaterials has led to advancements in many different biomedical applications, and it may also help cancer vaccines overcome the various aforementioned challenges. Here, we discuss the rational design and clinical status of several classes of cancer vaccines (i.e. DNA, mRNA, peptide/protein, cell-based), along with novel biomaterial-based delivery platforms that improve their safety and efficacy. Further, strategies for designing new platforms for personalized cancer vaccines are also considered.

show abstract

DNA Vaccines for the Induction of Immune Responses in Mucosal Tissues

Cited by 11 publications

References 271 publications

Current engineering and clinical aspects of needle-free injectors: A review

Current engineering and clinical aspects of needle-free injectors: A review

Mucosal vaccines and technology

Biomaterials for vaccine-based cancer immunotherapy

Contact Info

Product

Resources

About